Participants: ≥18 years, active CNV secondary to pathologic myopia, BCVA 20/32-20/320
Intervention:
Group 1: Intravitreal ranibizumab 0.5mg (VA stabilisation criteriae)
Group 2: Intravitreal ranibizumab 0.5mg (Disease activity criteriae)
Group 3: Verteporfin PDT + intravitreal ranibizumab from 3 months onwards (Disease activity criteriae)
Regime in groups 1 and 2: injection on Day 1 and Month 1, then PRN depending on retreatment criteria
Source Archive